Author:
Ganapati Arvind,Arya Suvrat,Gupta Nikhil,Patil Abhishek,Chebbi Pramod,Doley Daisy,Jeevanagi Sachin R,Sahu Rahul,Mandal Santosh K
Publisher
Springer Science and Business Media LLC
Reference25 articles.
1. Axial spondyloarthritis;Navarro-Compán V;Ann Rheum Dis,2021
2. 2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis;Ward MM;Arthritis Care Res (Hoboken),2019
3. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial;van der Heijde D;Lancet,2019
4. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial;Deodhar A;Lancet,2022
5. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study;van der Heijde D;Ann Rheum Dis,2017